The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells
Open Access
- 1 July 2020
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 14, 3099-3110
Abstract
Purpose: As radiation therapy is widely used for the management of pancreatic cancer, identifying novel targets to improve the radiosensitivity of cancer cells is beneficial. Rosiglitazone, a specific peroxisome proliferator-activated receptor γ (PPARγ) agonist, has an inhibitory effect on various types of cancer cells. The purpose of this paper is to investigate the effect of rosiglitazone on the radiosensitivity of pancreatic cancer cells and the potential mechanism. Materials and Methods: PPARγ expression in pancreatic cancer and adjacent tissues was evaluated using immunohistochemistry analysis. The viability, migration and invasion ability of PANC1 and PaTu8988 cells were detected using MTT assay, scratch-wound assay and transwell invasion assay. The effect of rosiglitazone on radiosensitivity of the cells was determined using the clonogenic assay. PANC1 cells were inoculated into BALB/c mice to establish tumors. Microarray was used to investigate changes of genes involved. Results: Higher PPARγ expression was demonstrated in pancreatic cancer tissues compared with para-carcinoma tissues. Rosiglitazone inhibited the cell viability and enhanced the radiation-induced anti-migration and anti-invasion effect. Rosiglitazone potentiated the radiosensitivity of pancreatic cancer cells and PANC1 xenografts. Microarray analysis revealed that rosiglitazone plus radiation altered the expression of multiple genes and affected multiple pathways. Conclusion: Rosiglitazone enhances the radiosensitivity of human pancreatic cancer cells in vitro and in vivo via complex mechanisms.Keywords
This publication has 39 references indexed in Scilit:
- Recent progress in pancreatic cancerCA: A Cancer Journal for Clinicians, 2013
- Rosiglitazone and AS601245 Decrease Cell Adhesion and Migration through Modulation of Specific Gene Expression in Human Colon Cancer CellsPLOS ONE, 2012
- Protein Kinase CK2 Triggers Cytosolic Zinc Signaling Pathways by Phosphorylation of Zinc Channel ZIP7Science Signaling, 2012
- The Effects of Rosiglitazone on Osteoblastic Differentiation, Osteoclast Formation and Bone ResorptionMolecules and Cells, 2012
- Cancer and Radiation Therapy: Current Advances and Future DirectionsInternational Journal of Medical Sciences, 2012
- Peroxisome proliferator-activated receptors and cancer: challenges and opportunitiesBritish Journal of Pharmacology, 2011
- Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cellsBiochemical and Biophysical Research Communications, 2010
- Combined Low Doses of PPARγ and RXR Ligands Trigger an Intrinsic Apoptotic Pathway in Human Breast Cancer CellsThe American Journal of Pathology, 2009
- PPARγ, PTEN, and the Fight against CancerPPAR Research, 2008
- Selective Cooperation between Fatty Acid Binding Proteins and Peroxisome Proliferator-Activated Receptors in Regulating TranscriptionMolecular and Cellular Biology, 2002